3D organ-on-a-chip: The convergence of microphysiological systems and organoids
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Medicine today faces the combined challenge of an increasing number of untreatable diseases and fewer drugs reaching the clinic. While pharmaceutical companies have increased the number of drugs in early development and entering phase I of clinical trials, fewer actually successfully pass phase III and launch into the market. In fact, only 1 out of every 9 drugs entering phase I will launch. In vitro preclinical tests are used to predict earlier and better the potential of new drugs and thus avoid expensive clinical trial phases. The most recent developments favor 3D cell culture and human stem cell biology. These 3D humanized models known as organoids better mimic the 3D tissue architecture and physiological cell behavior of healthy and disease models, but face critical issues in production such as small-scale batches, greater costs (when compared to monolayer cultures) and reproducibility. To become the gold standard and most relevant biological model for drug discovery and development, organoid technology needs to integrate biological culture processes with advanced microtechnologies, such as microphysiological systems based on microfluidics technology. Microphysiological systems, known as organ-on-a-chip, mimic physiological conditions better than conventional cell culture models since they can emulate perfusion, mechanical and other parameters crucial for tissue and organ physiology. In addition, they reduce labor cost and human error by supporting automated operation and reduce reagent use in miniaturized culture systems. There is thus a clear advantage in combining organoid culture with microsystems for drug development. The main objective of this review is to address the recent advances in organoids and microphysiological systems highlighting crucial technologies for reaching a synergistic strategy, including bioprinting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To date, MPS models have been developed for the majority of human tissues and organs, and have also been established to study a diverse range of malignancies, including cancer (Baptista et al., 2022; Hachey et al. (2021; 2024); Jiang et al., 2024; Haque et al., 2022; Shen et al., 2023; Flont et al., 2023; Straehla et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Baptista et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 1×
“Using adult stem cells (lgr5 positive cells) from the human intestine biopsy seeded on matrigel, these stem cells are capable of anchoring on extracellular matrix components of matrigel mimicking the epithelial polarity of intestine without a mesenchymal niche (Sato et al., 2009).”
BackgroundCerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372 · cited 1×
“This organoid recapitulates human cortical development in healthy and disease states (Lancaster et al., 2013).”
BackgroundReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 1×
“The device was capable of simulating breathing-type movements and responding to pathogen stimulus (Huh et al., 2010).”
BackgroundEngineering Flows in Small Devices: Microfluidics Toward a Lab-on-a-Chip
Stone, H. A., Stroock, A. D., & Ajdari, A. (2004) · Annual Review of Fluid Mechanics · doi:10.1146/annurev.fluid.36.050802.122124 · Cited by 3,666 · cited 1×
“the microchannels mimic the pressures exerted by vascularization, required for cell differentiation (Stone et al., 2004).”
BackgroundHow to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“, 94% of drugs fail in the clinical trial phases (Paul et al., 2010; Scannell et al., 2012), leading to unsustainable costs in the healthcare system and drugs with low efficacy and safety to the population.”
BackgroundModeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196 · cited 1×
“Organoids can better predict ef fi cacy and safety, improving the quality of preclinical tests before human clinical trials (Clevers, 2016).”
BackgroundHuman organoids: model systems for human biology and medicine
Kim, J., Koo, B.-K., & Knoblich, J. A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0259-3 · Cited by 2,187 · cited 1×
“3D cell culture models, more specifically, organoids, can recreate human 3D tissue architecture and spatially and temporally recapitulate morphogenetic events due to human stem cell differentiation (Kim et al., 2020) while animal models are not predictable models for several human diseases and physiological responses,…”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“An analysis of hundreds of drugs that failed in the later stage of drug development found that the preliminary assays conducted in rats and dogs were only able to predict human toxicity in 71% of cases (Olson et al., 2000).”
BackgroundDiagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 2×
“To reach approval, the novel drug must show safety and effectiveness in humans (Scannell et al., 2012).”
BackgroundDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Using iPS derived cells from patients or even primary cells from intestine or tumor biopsies, it is possible to recapitulate the disease development and genetic signatures from the disease of origin (Drost and Clevers, 2018).”
BackgroundHuman organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589 · cited 3×
“Organ-on-a-chip technologies are based on microfluidic devices seeded with cells maintained under constant fluid flow (Ingber, 2022).”
BackgroundInfluentialDesigner matrices for intestinal stem cell and organoid culture
Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M. E., Ordóñez-Morán, P., Clevers, H., & Lutolf, M. P. (2016) · Nature · doi:10.1038/nature20168 · Cited by 1,426
Cell diversity and network dynamics in photosensitive human brain organoids
Quadrato, G., Nguyen, T., Macosko, E. Z., Sherwood, J. L., Min Yang, S., Berger, D. R., Maria, N., Scholvin, J., Goldman, M., Kinney, J. P., et al. (2017) · Nature · doi:10.1038/nature22047 · Cited by 1,321 · cited 2×
“The subsequent articles showed a diversity of cell types related to the human cerebral cortex (Quadrato et al., 2017; Velasco et al., 2019) with a correlation of genetic variability according to donor cells (Velasco et al.”
BackgroundProgress and potential in organoid research
Rossi, G., Manfrin, A., & Lutolf, M. P. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0051-9 · Cited by 1,182 · cited 1×
“In addition to the requirement that organoids be derived from stem cells or primary sources, they should have at least one physiologic function from the organ of origin (Rossi et al., 2018).”
BackgroundJacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
BackgroundIndividual brain organoids reproducibly form cell diversity of the human cerebral cortex
Velasco, S., Kedaigle, A. J., Simmons, S. K., Nash, A., Rocha, M., Quadrato, G., Paulsen, B., Nguyen, L., Adiconis, X., Regev, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1289-x · Cited by 1,094 · cited 2×
“, 2019) with a correlation of genetic variability according to donor cells (Velasco et al., 2019).”
BackgroundModelling human development and disease in pluripotent stem-cell-derived gastric organoids
McCracken, K. W., Catá, E. M., Crawford, C. M., Sinagoga, K. L., Schumacher, M., Rockich, B. E., Tsai, Y.-H., Mayhew, C. N., Spence, J. R., Zavros, Y., et al. (2014) · Nature · doi:10.1038/nature13863 · Cited by 980
Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip
Zhang, Y. S., Arneri, A., Bersini, S., Shin, S.-R., Zhu, K., Goli-Malekabadi, Z., Aleman, J., Colosi, C., Busignani, F., Dell'Erba, V., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.003 · Cited by 951 · cited 1×
“As 3D cell culture technologies advance, as well as our understanding of protocols for inducing morphogenesis, the complexity of organoids increases, including in the diversity of cell types used and, consequently, their function, compared to the organ of origin (Mccracken et al., 2014; Zhang et al., 2016; Achberger e…”
BackgroundFlow-enhanced vascularization and maturation of kidney organoids in vitro
Homan, K. A., Gupta, N., Kroll, K. T., Kolesky, D. B., Skylar-Scott, M., Miyoshi, T., Mau, D., Valerius, M. T., Ferrante, T., Bonventre, J. V., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0325-y · Cited by 939 · cited 2×
“The increase of cell differentiation impacts positively on the development of tissuespecific architecture, maturation and the functionality of organoids (Homan et al., 2019; Wang et al., 2020).”
BackgroundNephron organoids derived from human pluripotent stem cells model kidney development and injury
Morizane, R., Lam, A. Q., Freedman, B. S., Kishi, S., Valerius, M. T., & Bonventre, J. V. (2015) · Nature Biotechnology · doi:10.1038/nbt.3392 · Cited by 927
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
BackgroundIn vitro generation of human pluripotent stem cell derived lung organoids
Dye, B. R., Hill, D. R., Ferguson, M. A., Tsai, Y.-H., Nagy, M. S., Dyal, R., Wells, J. M., Mayhew, C. N., Nattiv, R., Klein, O. D., et al. (2015) · eLife · doi:10.7554/elife.05098 · Cited by 819 · cited 1×
“The lung organoid derived from iPS was described soon after, showing epithelial and mesenchymal compartments, together with tissue architecture similar to native lung (Dye et al., 2015; Chen et al., 2017).”
BackgroundPatient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · cited 1×
“, 2020), lung cancer (Kim et al., 2019), breast cancer (Campaner et al.”
BackgroundGuided self-organization and cortical plate formation in human brain organoids
Lancaster, M. A., Corsini, N. S., Wolfinger, S., Gustafson, E. H., Phillips, A. W., Burkard, T. R., Otani, T., Livesey, F. J., & Knoblich, J. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3906 · Cited by 783 · cited 1×
“Using bioengineering approaches, such as for example, synthetic hydrogels, desired tissue architecture can be generated from a guided stem cell differentiation, increasing reproducibility (Lancaster et al., 2017).”
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.10.010 · Cited by 755 · cited 1×
“Using patient-derived organoids allows the discovery of new biomarkers for diseases and test drugs in vitro before patient treatment (personalized medicine) (Yao et al., 2020).”
BackgroundHomeostatic mini-intestines through scaffold-guided organoid morphogenesis
Nikolaev, M., Mitrofanova, O., Broguiere, N., Geraldo, S., Dutta, D., Tabata, Y., Elci, B., Brandenberg, N., Kolotuev, I., Gjorevski, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2724-8 · Cited by 755
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Yi, H.-G., Jeong, Y. H., Kim, Y., Choi, Y.-J., Moon, H. E., Park, S. H., Kang, K. S., Bae, M., Jang, J., Youn, H., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0363-x · Cited by 634
A three-dimensional model of human lung development and disease from pluripotent stem cells
Chen, Y.-W., Huang, S. X., de Carvalho, A. L. R. T., Ho, S.-H., Islam, M. N., Volpi, S., Notarangelo, L. D., Ciancanelli, M., Casanova, J.-L., Bhattacharya, J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3510 · Cited by 608 · cited 1×
“The lung organoid derived from iPS was described soon after, showing epithelial and mesenchymal compartments, together with tissue architecture similar to native lung (Dye et al., 2015; Chen et al., 2017).”
BackgroundModeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537 · cited 1×
“This increase of cell diversity allowed the organoids recapitulate the main steps of steatohepatitis, including steatosis, inflammation, and fibrosis phenotypes (Ouchi et al., 2019; Wang et al., 2019).”
BackgroundReproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511 · cited 3×
“The most common problems are absence of efficacy and unforeseen side effects, leading to withdrawal of drugs from the market (Jang et al., 2019).”
BackgroundInfluentialModeling Patient-Derived Glioblastoma with Cerebral Organoids
Linkous, A., Balamatsias, D., Snuderl, M., Edwards, L., Miyaguchi, K., Milner, T., Reich, B., Cohen-Gould, L., Storaska, A., Nakayama, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.063 · Cited by 502 · cited 1×
“The authors observed forming tumors close to patient glioblastomas (Linkous et al., 2019).”
BackgroundLee, J.-H., Bhang, D. H., Beede, A., Huang, T. L., Stripp, B. R., Bloch, K. D., Wagers, A. J., Tseng, Y.-H., Ryeom, S., & Kim, C. F. (2014) · Cell · doi:10.1016/j.cell.2013.12.039 · Cited by 490 · cited 1×
“Pioneer research in the field of lung organoids is derived from recent studies describing 3D coculture techniques of stem cell subpopulations with endothelial cells (Lee et al., 2014).”
BackgroundRecapitulating macro-scale tissue self-organization through organoid bioprinting
Brassard, J. A., Nikolaev, M., Hübscher, T., Hofer, M., & Lutolf, M. P. (2021) · Nature Materials · doi:10.1038/s41563-020-00803-5 · Cited by 469 · cited 1×
“In a similar approach, Brassard and collaborators Brassard et al. (2021) presented a new 3D bioprinting platform named bioprinting-assisted tissue emergence (BATE).”
BackgroundPancreatic cancer organoids recapitulate disease and allow personalized drug screening
Driehuis, E., van Hoeck, A., Moore, K., Kolders, S., Francies, H. E., Gulersonmez, M. C., Stigter, E. C. A., Burgering, B., Geurts, V., Gracanin, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911273116 · Cited by 459 · cited 1×
“, 2017) and characterized by DNA and RNA sequencing (Driehuis et al., 2019), allowing drug testing before patient treatment of genetic similar tumors.”
BackgroundOrgan-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437 · cited 1×
“Their criticisms center on the poor physiological resemblance to healthy or diseased human tissue (Zhang and Radisic, 2017), and for animal models, their lengthy time for results, high fi nancial costs and ethical issues.”
BackgroundCellular extrusion bioprinting improves kidney organoid reproducibility and conformation
Lawlor, K. T., Vanslambrouck, J. M., Higgins, J. W., Chambon, A., Bishard, K., Arndt, D., Er, P. X., Wilson, S. B., Howden, S. E., Tan, K. S., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-00853-9 · Cited by 435 · cited 1×
“In a model of 3D bioprinted kidney organoids, the authors showed that the bioprinting process was accurate and that the organoids had consistent nephron patterning in a large scale tissue (Lawlor et al., 2021).”
BackgroundProgenitor identification and SARS-CoV-2 infection in human distal lung organoids
Salahudeen, A. A., Choi, S. S., Rustagi, A., Zhu, J., van Unen, V., de la O, S. M., Flynn, R. A., Margalef-Català, M., Santos, A. J. M., Ju, J., et al. (2020) · Nature · doi:10.1038/s41586-020-3014-1 · Cited by 416
Crespo, M., Vilar, E., Tsai, S.-Y., Chang, K., Amin, S., Srinivasan, T., Zhang, T., Pipalia, N. H., Chen, H. J., Witherspoon, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4355 · Cited by 399 · cited 1×
“Furthermore, several biobanks have been created (Crespo et al., 2017) and characterized by DNA and RNA sequencing (Driehuis et al.”
BackgroundCho, A.-N., Jin, Y., An, Y., Kim, J., Choi, Y. S., Lee, J. S., Kim, J., Choi, W.-Y., Koo, D.-J., Yu, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24775-5 · Cited by 397 · cited 1×
“, 2021) or even with biomaterials derived from decellularized extracellular matrix (Cho et al., 2021; Kim et al., 2022).”
BackgroundAchberger, K., Probst, C., Haderspeck, J., Bolz, S., Rogal, J., Chuchuy, J., Nikolova, M., Cora, V., Antkowiak, L., Haq, W., et al. (2019) · eLife · doi:10.7554/elife.46188 · Cited by 380
Multiorgan-on-a-Chip: A Systemic Approach To Model and Decipher Inter-Organ Communication
Picollet-D’hahan, N., Zuchowska, A., Lemeunier, I., & Le Gac, S. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.11.014 · Cited by 379
Human gastric cancer modelling using organoids
Seidlitz, T., Merker, S. R., Rothe, A., Zakrzewski, F., von Neubeck, C., Grützmann, K., Sommer, U., Schweitzer, C., Schölch, S., Uhlemann, H., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-314549 · Cited by 328 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
BackgroundRethinking organoid technology through bioengineering
Garreta, E., Kamm, R. D., Chuva de Sousa Lopes, S. M., Lancaster, M. A., Weiss, R., Trepat, X., Hyun, I., & Montserrat, N. (2021) · Nature Materials · doi:10.1038/s41563-020-00804-4 · Cited by 324 · cited 5×
“The culture environment of organoids at the moment suffers from the absence of vascularization, reduced organoid lifespan, and variability of tissue-specific architecture and functionality (Garreta et al., 2021).”
BackgroundInfluentialOrganoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1376 · Cited by 316 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
Backgroundde Witte, C. J., Espejo Valle-Inclan, J., Hami, N., Lõhmussaar, K., Kopper, O., Vreuls, C. P. H., Jonges, G. N., van Diest, P., Nguyen, L., Clevers, H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107762 · Cited by 303
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease
Ramli, M. N. B., Lim, Y. S., Koe, C. T., Demircioglu, D., Tng, W., Gonzales, K. A. U., Tan, C. P., Szczerbinska, I., Liang, H., Soe, E. L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.010 · Cited by 278
Synergistic Engineering: Organoids Meet Organs-on-a-Chip
Takebe, T., Zhang, B., & Radisic, M. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.016 · Cited by 258 · cited 3×
“Besides better control of cell function, microfluidics also allows a real time monitoring of responses through sensors (Takebe et al., 2017).”
BackgroundInfluentialEvaluation of variability in human kidney organoids
Phipson, B., Er, P. X., Combes, A. N., Forbes, T. A., Howden, S. E., Zappia, L., Yen, H.-J., Lawlor, K. T., Hale, L. J., Sun, J., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0253-2 · Cited by 253 · cited 1×
“Relevant porgress was reached for kidney organoids (Morizane et al., 2015; Phipson et al., 2018; Facioli et al., 2021; Ryan et al., 2021) for tumor organoids as a model of tumorigenesis (Francies et al.”
BackgroundPaek, J., Park, S. E., Lu, Q., Park, K.-T., Cho, M., Oh, J. M., Kwon, K. W., Yi, Y.-S., Song, J. W., Edelstein, H. I., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00686 · Cited by 238 · cited 1×
“Using a perfusable 3D microvascular beds containing a co-culture of human vascular endothelial cells and fibroblasts, the authors showed that the integration of microvascular beds with other cell types recapitulates organspecific cellular heterogeneity and structural organization of vascularized human tissues, such as…”
BackgroundNovel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234 · cited 1×
“, 2020), including co-culture of human hepatic progenitor and stellate cells for the simulation of a fibrotic condition (Leite et al., 2016).”
BackgroundMarx, U. (2020) · ALTEX · doi:10.14573/altex.2001241 · Cited by 218 · cited 2×
“Due to the high failure rate faced today by pharmaceutical companies, the process has been revised as a whole and raised important issues of the preclinical stage (Marx et al., 2020), more specifically that preclinical results come from tests with cells of non-human origin (cell culture and animal models) and their mi…”
Renner, H., Grabos, M., Becker, K. J., Kagermeier, T. E., Wu, J., Otto, M., Peischard, S., Zeuschner, D., TsyTsyura, Y., Disse, P., et al. (2020) · eLife · doi:10.7554/elife.52904 · Cited by 215 · cited 1×
“They attributed this variability to the innate donor variability found in iPS (Renner et al., 2020).”
BackgroundWang, S., Wang, X., Tan, Z., Su, Y., Liu, J., Chang, M., Yan, F., Chen, J., Chen, T., Li, C., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0242-8 · Cited by 210
3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels
Mollica, P. A., Booth-Creech, E. N., Reid, J. A., Zamponi, M., Sullivan, S. M., Palmer, X.-L., Sachs, P. C., & Bruno, R. D. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.017 · Cited by 206 · cited 1×
“Recent studies of 3D bioprinted mammary organoids in hydrogels showed a better efficiency when compared to nonbioprinted organoids (Mollica et al., 2019; Reid et al., 2019).”
Background3D Printing of Inertial Microfluidic Devices
Razavi Bazaz, S., Rouhi, O., Raoufi, M. A., Ejeian, F., Asadnia, M., Jin, D., & Ebrahimi Warkiani, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-62569-9 · Cited by 204
A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®
Bircsak, K. M., DeBiasio, R., Miedel, M., Alsebahi, A., Reddinger, R., Saleh, A., Shun, T., Vernetti, L. A., & Gough, A. (2021) · Toxicology · doi:10.1016/j.tox.2020.152667 · Cited by 192 · cited 3×
“In general, the process is not automated, with few exceptions (Bircsak et al., 2021).”
BackgroundMethodInfluentialDeveloping Organoids from Ovarian Cancer as Experimental and Preclinical Models
Maenhoudt, N., Defraye, C., Boretto, M., Jan, Z., Heremans, R., Boeckx, B., Hermans, F., Arijs, I., Cox, B., Van Nieuwenhuysen, E., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.004 · Cited by 186 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
BackgroundKim, J. W., Nam, S. A., Yi, J., Kim, J. Y., Lee, J. Y., Park, S., Sen, T., Choi, Y., Lee, J. Y., Kim, H. L., et al. (2022) · Advanced Science · doi:10.1002/advs.202103526 · Cited by 185
An organoid-based organ-repurposing approach to treat short bowel syndrome
Sugimoto, S., Kobayashi, E., Fujii, M., Ohta, Y., Arai, K., Matano, M., Ishikawa, K., Miyamoto, K., Toshimitsu, K., Takahashi, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03247-2 · Cited by 175 · cited 1×
“, 2021) and for mimicking different parts of intestine (Xie and Wu, 2016) such as the small intestine colon as a regenerative strategy for short bowel syndrome (Sugimoto et al., 2021).”
BackgroundSilva, A. C., Matthys, O. B., Joy, D. A., Kauss, M. A., Natarajan, V., Lai, M. H., Turaga, D., Blair, A. P., Alexanian, M., Bruneau, B. G., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.11.007 · Cited by 167 · cited 1×
“As 3D cell culture technologies advance, as well as our understanding of protocols for inducing morphogenesis, the complexity of organoids increases, including in the diversity of cell types used and, consequently, their function, compared to the organ of origin (Mccracken et al., 2014; Zhang et al., 2016; Achberger e…”
BackgroundNanki, Y., Chiyoda, T., Hirasawa, A., Ookubo, A., Itoh, M., Ueno, M., Akahane, T., Kameyama, K., Yamagami, W., Kataoka, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69488-9 · Cited by 165
Maloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A. P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., et al. (2020) · Micromachines · doi:10.3390/mi11020208 · Cited by 161 · cited 1×
“Other studies have bioprinted organoids for drug screening assays (Maloney et al., 2020; Bouwmeester et al., 2021).”
BackgroundBioprinting Perfusion-Enabled Liver Equivalents for Advanced Organ-on-a-Chip Applications
Grix, T., Ruppelt, A., Thomas, A., Amler, A.-K., Noichl, B., Lauster, R., & Kloke, L. (2018) · Genes · doi:10.3390/genes9040176 · Cited by 151 · cited 1×
“There is also an increasing interest in the application of 3D bioprinting for the production of organoids in a high throughput system for drug screening tests (Grix et al., 2018).”
BackgroundReproducible generation of human midbrain organoids for in vitro modeling of Parkinson’s disease
Nickels, S., Modamio, J., Mendes-Pinheiro, B., Monzel, A. S., Betsou, F., & Schwamborn, J. C. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.101870 · Cited by 138 · cited 2×
“The first described protocol for cerebral organoid in 2013 was time and cost consuming and since then some degree of optimization to reduce batch-batch variability has been undertaken (Nickels et al., 2020), including the use of bioengineering approaches (Lancaster et al.”
BackgroundMethodEstablishment of intestinal organoid cultures modeling injury-associated epithelial regeneration
Qu, M., Xiong, L., Lyu, Y., Zhang, X., Shen, J., Guan, J., Chai, P., Lin, Z., Nie, B., Li, C., et al. (2021) · Cell Research · doi:10.1038/s41422-020-00453-x · Cited by 138
Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
Haque, M. R., Wessel, C. R., Leary, D. D., Wang, C., Bhushan, A., & Bishehsari, F. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00370-6 · Cited by 137 · cited 1×
“Furthermore, stroma-depleting agents resulted in an increased loss of cancer cell viability in the chip device in comparison to monolayer culture (Haque et al., 2022).”
BackgroundPDX-derived organoids model in vivo drug response and secrete biomarkers
Huang, L., Bockorny, B., Paul, I., Akshinthala, D., Frappart, P.-O., Gandarilla, O., Bose, A., Sanchez-Gonzalez, V., Rouse, E. E., Lehoux, S. D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135544 · Cited by 128 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
Background3D Printing Techniques and Their Applications to Organ-on-a-Chip Platforms: A Systematic Review
Carvalho, V., Gonçalves, I., Lage, T., Rodrigues, R. O., Minas, G., Teixeira, S. F. C. F., Moita, A. S., Hori, T., Kaji, H., & Lima, R. A. (2021) · Sensors · doi:10.3390/s21093304 · Cited by 125 · cited 1×
“Over the last years, the main methods used to develop microfluidics devices were conventional manufacturing techniques, such as photo-patterning, self-assembly and soft lithography (Carvalho et al., 2021).”
MethodOrganoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L., Huang, L., Akshinthala, D., Perea, S., Gonzalez, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 121 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
BackgroundModeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis
Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J., & Akilesh, S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.011 · Cited by 105 · cited 1×
“The combination of primary human clear cell renal carcinoma with human endothelial cells in a chip results in the molecular signature of donor variation (Miller et al., 2018).”
BackgroundEngineering spatial-organized cardiac organoids for developmental toxicity testing
Hoang, P., Kowalczewski, A., Sun, S., Winston, T. S., Archilla, A. M., Lemus, S. M., Ercan-Sencicek, A. G., Gupta, A. R., Liu, W., Kontaridis, M. I., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.03.013 · Cited by 100 · cited 1×
“Renal tubular organoids and iPS-derived cardiac organoids showed responsiveness ti drug treatment (Guo et al., 2020; Hoang et al., 2021).”
BackgroundPancreatic cancer‐derived organoids – a disease modeling tool to predict drug response
Frappart, P., Walter, K., Gout, J., Beutel, A. K., Morawe, M., Arnold, F., Breunig, M., Barth, T. F. E., Marienfeld, R. B., Schulte, L.-A., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620905183 · Cited by 94
Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment
Campaner, E., Zannini, A., Santorsola, M., Bonazza, D., Bottin, C., Cancila, V., Tripodo, C., Bortul, M., Zanconati, F., Schoeftner, S., et al. (2020) · Cancers · doi:10.3390/cancers12123869 · Cited by 92
A 3D bioprinter platform for mechanistic analysis of tumoroids and chimeric mammary organoids
Reid, J. A., Palmer, X.-L., Mollica, P. A., Northam, N., Sachs, P. C., & Bruno, R. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-43922-z · Cited by 89 · cited 1×
“Recent studies of 3D bioprinted mammary organoids in hydrogels showed a better ef fi ciency when compared to non-bioprinted organoids (Mollica et al., 2019; Reid et al., 2019).”
Kim, J.-H., An, G. H., Kim, J.-Y., Rasaei, R., Kim, W. J., Jin, X., Woo, D.-H., Han, C., Yang, S.-R., Kim, J.-H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00439-7 · Cited by 87
Use of 3D Organoids as a Model to Study Idiopathic Form of Parkinson’s Disease
Chlebanowska, P., Tejchman, A., Sułkowski, M., Skrzypek, K., & Majka, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030694 · Cited by 86 · cited 1×
“Midbrain organoids are capable of recapitulating dopaminergic neuron and astrocyte differentiation, serving as a model for Parkinson disease (Chlebanowska et al., 2020; Nickels et al., 2020).”
BackgroundHuman cerebral organoids as a therapeutic drug screening model for Creutzfeldt–Jakob disease
Groveman, B. R., Ferreira, N., Foliaki, S. T., Walters, R. O., Winkler, C. W., Race, B., Hughson, A. G., Zanusso, G., & Haigh, C. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-84689-6 · Cited by 83 · cited 1×
“Besides, brain organoids were responsive to an established anti-prion compound, supporting their potential as a drug screening model (Groveman et al., 2021).”
Generation of intestinal organoids derived from human pluripotent stem cells for drug testing
Yoshida, S., Miwa, H., Kawachi, T., Kume, S., & Takahashi, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-63151-z · Cited by 82 · cited 1×
“Organoids represent a powerful tool to model human tissues and organs at the cellular and molecular levels, with applications in drug discovery, development and testing (Yoshida et al., 2020).”
MethodDrug Sensitivity Assays of Human Cancer Organoid Cultures
Francies, H. E., Barthorpe, A., McLaren-Douglas, A., Barendt, W. J., & Garnett, M. J. (2016) · Methods in Molecular Biology · doi:10.1007/7651_2016_10 · Cited by 81 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
BackgroundKim, H., Im, I., Jeon, J. S., Kang, E.-H., Lee, H.-A., Jo, S., Kim, J.-W., Woo, D.-H., Choi, Y. J., Kim, H. J., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121575 · Cited by 81 · cited 2×
“, 2021) or even with biomaterials derived from decellularized extracellular matrix (Cho et al., 2021; Kim et al., 2022).”
BackgroundJian, M., Ren, L., He, G., Lin, Q., Tang, W., Chen, Y., Chen, J., Liu, T., Ji, M., Wei, Y., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02407-8 · Cited by 78
Organoid Cultures Derived From Patients With Papillary Thyroid Cancer
Chen, D., Tan, Y., Li, Z., Li, W., Yu, L., Chen, W., Liu, Y., Liu, L., Guo, L., Huang, W., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab020 · Cited by 77 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
BackgroundBi, J., Newtson, A. M., Zhang, Y., Devor, E. J., Samuelson, M. I., Thiel, K. W., & Leslie, K. K. (2021) · Cancers · doi:10.3390/cancers13122901 · Cited by 72
Bioprinting a 3D vascular construct for engineering a vessel-on-a-chip
Abudupataer, M., Chen, N., Yan, S., Alam, M. F., Shi, Y., Wang, L., Lai, H., Li, J., Zhu, K., & Wang, C. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0460-3 · Cited by 71 · cited 1×
“Cells showed high viability and when compared to traditional cell culture methods, the 2D constructs had an upregulated expression of vascular proteins (Abudupataer et al., 2019).”
BackgroundHigh-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., Frydenberg, M., Grummet, J., Sandhu, S., Hickey, T. E., et al. (2021) · SLAS Discovery · doi:10.1177/24725552211020668 · Cited by 69 · cited 1×
“Several studies have demonstrated maintenance of the genomic alterations from the original tumor during long-term culture (Choo et al., 2021), including those from ovarian cancer (Nanki et al.”
BackgroundBuilding blocks for a European Organ-on-Chip roadmap
Mastrangeli, M. (2019) · ALTEX · doi:10.14573/altex.1905221 · Cited by 66 · cited 1×
“More importantly, such predictable models can capture specific characteristics of a person’s disease, individual responses to drugs, including sideeffects (Mastrangeli et al., 2019).”
BackgroundTan, P., Wang, M., Zhong, A., Wang, Y., Du, J., Wang, J., Qi, L., Bi, Z., Zhang, P., Lin, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01999-9 · Cited by 65
Current Challenges and Controversies in Drug-Induced Liver Injury
Corsini, A., Ganey, P. E., Ju, C., Kaplowitz, N., Pessayre, D., Roth, R. A., Watkins, P. B., Albassam, M., Liu, B., Stancic, S., et al. (2012) · Drug Safety · doi:10.1007/bf03261997 · Cited by 63 · cited 1×
“2019), tumors and obesity, but others mainly require better, more accurate models for the prediction of toxicity (Corsini et al., 2012), a major cause of failure in drug development.”
BackgroundA Human Organoid Model of Aggressive Hepatoblastoma for Disease Modeling and Drug Testing
Saltsman, J. A., Hammond, W. J., Narayan, N. J. C., Requena, D., Gehart, H., Lalazar, G., LaQuaglia, M. P., Clevers, H., & Simon, S. (2020) · Cancers · doi:10.3390/cancers12092668 · Cited by 59 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
BackgroundLachaux, J., Alcaine, C., Gómez-Escoda, B., Perrault, C. M., Duplan, D. O., Wu, P.-Y. J., Ochoa, I., Fernandez, L., Mercier, O., Coudreuse, D., et al. (2017) · Lab on a Chip · doi:10.1039/c7lc00488e · Cited by 57
Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer
Xie, B., & Wu, A. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.191782 · Cited by 54
Guo, H., Deng, N., Dou, L., Ding, H., Criswell, T. L., Atala, A., Furdui, C. M., & Zhang, Y. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01468 · Cited by 53 · cited 1×
“Renal tubular organoids and iPS-derived cardiac organoids showed responsiveness ti drug treatment (Guo et al., 2020; Hoang et al., 2021).”
BackgroundAdvancing lung organoids for COVID-19 research
van der Vaart, J., Lamers, M. M., Haagmans, B. L., & Clevers, H. C. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049060 · Cited by 53
Current Challenges and Controversies in Drug-Induced Liver Injury
Corsini, A., Ganey, P. E., Ju, C., et al. (2012) · Drug Safety · doi:10.2165/11632970-000000000-00000 · Cited by 50
Bioprinting of Human Liver‐Derived Epithelial Organoids for Toxicity Studies
Bouwmeester, M. C., Bernal, P. N., Oosterhoff, L. A., van Wolferen, M. E., Lehmann, V., Vermaas, M., Buchholz, M., Peiffer, Q. C., Malda, J., van der Laan, L. J. W., et al. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100327 · Cited by 46 · cited 2×
“Recently, a bioprinted model of human hepatocyte-like cells derived from organoids was tested under exposition of a known hepatotoxic compound, showing an expected decrease in cell viability (Bouwmeester et al., 2021).”
BackgroundVascular deficiencies in renal organoids and ex vivo kidney organogenesis
Ryan, A. R., England, A. R., Chaney, C. P., Cowdin, M. A., Hiltabidle, M., Daniel, E., Gupta, A. K., Oxburgh, L., Carroll, T. J., & Cleaver, O. (2021) · Developmental Biology · doi:10.1016/j.ydbio.2021.04.009 · Cited by 44
Panoutsopoulos, A. A. (2020) · The Neuroscientist · doi:10.1177/1073858420960112 · Cited by 42 · cited 2×
“When organoids are close to each other, they can fuse, forming distinct and more complex structures (Panoutsopoulos, 2021).”
BackgroundSun, Y., Wu, Q., Dai, K., You, Y., & Jiang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00675-4 · Cited by 42 · cited 1×
“As 3D cell culture technologies advance, as well as our understanding of protocols for inducing morphogenesis, the complexity of organoids increases, including in the diversity of cell types used and, consequently, their function, compared to the organ of origin (Mccracken et al., 2014; Zhang et al., 2016; Achberger e…”
BackgroundDornhof, J., Zieger, V., Kieninger, J., Frejek, D., Zengerle, R., Urban, G. A., Kartmann, S., & Weltin, A. (2022) · Lab on a Chip · doi:10.1039/d2lc00705c · Cited by 41 · cited 1×
“Recently, MCF-7 spheroids were individually and precisely positioning into the microelectrode wells using a particular bioprinting approach for monitoring oxygen consumption in the absence of laminar flow (Dornhof et al., 2022).”
MethodMehta, V., Sudhakaran, S. V., & Rath, S. N. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00633 · Cited by 40
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma
Dijkstra, K. K., van den Berg, J. G., Weeber, F., van de Haar, J., Velds, A., Kaing, S., Peters, D. D. G. C., Eskens, F. A. L. M., de Groot, D.-J. A., Tesselaar, M. E. T., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.627819 · Cited by 38 · cited 1×
“, 2021) for tumor organoids as a model of tumorigenesis (Francies et al., 2016; Lee et al., 2018; Huang et al., 2020; Maenhoudt et al., 2020; Chen et al., 2021; Dijkstra et al., 2021; Tan et al., 2021).”
BackgroundTwo Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids
Spitalieri, P., Centofanti, F., Murdocca, M., Scioli, M. G., Latini, A., Cesare, S. D., Citro, G., Rossi, A., Orlandi, A., Miersch, S., et al. (2022) · Cells · doi:10.3390/cells11071235 · Cited by 32 · cited 1×
“Lung organoids as a model for fibrosis and SARS CoV-2 infection were used for drug testing (Kim et al., 2021; Spitalieri et al., 2022).”
MethodDevelopment of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma
Kazama, A., Anraku, T., Kuroki, H., Shirono, Y., Murata, M., Bilim, V. N., Ugolkov, A. V., Saito, K., & Tomita, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.8177 · Cited by 27 · cited 1×
“Organoids are now considered as avatars in personalized medicine (Seidlitz et al., 2018; Frappart et al., 2020; Jacob et al., 2020; Jian et al., 2020; Saltsman et al., 2020; Shi et al., 2020; Witte et al., 2020; Bi et al., 2021; Kazama et al., 2021; Grossman et al., 2022) with the potential to contribute to reducing t…”
BackgroundCreating rat hepatocyte organoid as an in vitro model for drug testing
He, Y.-T., Zhu, X.-L., Li, S.-F., Zhang, B.-Q., Li, Y., Wu, Q., Zhang, Y.-L., Zhou, Y.-Y., Li, L., Qi, Y.-N., et al. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i10.1184 · Cited by 22 · cited 1×
“Several models have been developed (He et al., 2020), including co-culture of human hepatic progenitor and stellate cells for the simulation of a fibrotic condition (Leite et al.”
BackgroundFacioli, R., Lojudice, F., Anauate, A. C., Maquigussa, E., Nishiura, J. L., Heilberg, I., Sogayar, M., & Boim, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252156 · Cited by 6 · cited 1×
“Relevant porgress was reached for kidney organoids (Morizane et al., 2015; Phipson et al., 2018; Facioli et al., 2021; Ryan et al., 2021) for tumor organoids as a model of tumorigenesis (Francies et al.”
Background
Cited by
Type 1 Diabetes Mellitus: A Review on Advances and Challenges in Creating Insulin Producing Devices
Oliveira, S. M. R., Rebocho, A., Ahmadpour, E., Nissapatorn, V., & Pereira, M. D. L. (2023) · Micromachines · doi:10.3390/mi14010151 · Cited by 103
“Moreover, an organoid-on-a-chip technology is also currently being considered, particularly for bioprinting and drug development [90].”
BackgroundLi, B., Tang, Y., Huang, Z., Ma, L., Song, J., & Xue, L. (2025) · Protein & Cell · doi:10.1093/procel/pwaf058 · Cited by 57
“Organoid-on-a-chip represent a next-generation biological model that combines the self-organizing properties of organoids with the engineering precision of organ-on-a-chip systems (Baptista et al., 2022).”
Imaging 3D cell cultures with optical microscopy
Hsieh, H.-C., Han, Q., Brenes, D., Bishop, K. W., Wang, R., Wang, Y., Poudel, C., Glaser, A. K., Freedman, B., Vaughan, J. C., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02647-w · Cited by 49
Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions
Visalakshan, R. M., Lowrey, M. K., Sousa, M. G. C., Helms, H. R., Samiea, A., Schutt, C. E., Moreau, J. M., & Bertassoni, L. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162905 · Cited by 35
Strategies for craniofacial tissue engineering: innovations for scalable bone regeneration
Vignolo, S. M., Roth, D. M., Wu, L., Cosgrove, J., & Bertassoni, L. E. (2025) · Plastic and Aesthetic Research · doi:10.20517/2347-9264.2025.09 · Cited by 76
Metadata
- Authors
- Baptista, L. S., Porrini, C., Kronemberger, G. S., Kelly, D. J., & Perrault, C. M.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Trinity College Dublin (IE)
- Royal College of Surgeons in Ireland (IE)
- Corresponding author
- Porrini, Constance
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-21
- Volume
- 10
- Pages
- 1043117-1043117
- ISSN
- 2296-634X (ISSN-L)
- PMC
- PMC9720174
- OpenAlex
- W4309740738
- Semantic Scholar
- 40a124d32fbb2a39a90bd951972e16bd4d47c56d
- Cited by
- 90
- References
- 106
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 22 · 2023: 15
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Update notices
- corrigendum (2024-01-26)
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Greater South Information System
- Funders
- H2020 Marie Skłodowska-Curie Actions
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- organ-on-a-chip, organoids, microphysiological systems, microfluidics, 3D cell culture, drug discovery, drug development, bioprinting, stem cell-derived models, reproducibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.